What is OneSource

OneSource provides education, access, and treatment support for people living with paroxysmal nocturnal hemoglobinuria (PNH) and their caregivers. It is staffed by Alexion Nurse Case Managers, who are registered nurses with healthcare and insurance experience. Alexion Pharmaceuticals developed this program to help patients obtain access to Soliris, and provide them with reliable information on PNH and Soliris®.

OneSource: The support you need — designed just for you

We know that living with and treating a rare disease like PNH can be very challenging for you and your healthcare providers. This is why we created OneSource. Our Nurse Case Managers are available to answer questions, provide support, and help facilitate solutions for you and your healthcare team every step of the way.

Alexion Nurse Case Managers are registered nurses with healthcare and insurance expertise. Nurse Case Managers will provide you with one-to-one support and education, whether you are exploring treatment options, getting ready to begin Soliris therapy, or currently being treated with Soliris. Even if you are not on Soliris, Nurse Case Managers can answer many of the questions you may have about PNH or insurance coverage. Just remember that your doctor is still your best resource when deciding whether Soliris therapy is right for you.





IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full prescribing information for SOLIRIS, including boxed WARNING regarding serious meningitis.